Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery. 



Biotechnology

Confo Therapeutics

Cedric Ververken

Geert Degruyter

Bruno Ranschaert

Thomas Fontaine

Richa Virmani

Caroline Segers

Andreas Busch

Stephen Dowd

Christel Menet

Frank Landolt

Paolo Vicini

Stephanie Staelens

Marc Moens

Leadership Team

Research and Development

Teams at Confo Therapeutics

Leadership Team

Research and Development

Research and Development